litlas
ログインアカウント作成

David S. Shames

2004–2025 年に発表

75
論文数
18,163
被引用数
61
h 指数
72
i10 指数

被引用数

David S. Shames の年別被引用数1971 年: 被引用 1 件2000 年: 被引用 1 件2002 年: 被引用 4 件2004 年: 被引用 2 件2005 年: 被引用 8 件2006 年: 被引用 16 件2007 年: 被引用 45 件2008 年: 被引用 64 件2009 年: 被引用 71 件2010 年: 被引用 87 件2011 年: 被引用 115 件2012 年: 被引用 115 件2013 年: 被引用 151 件2014 年: 被引用 126 件2015 年: 被引用 133 件2016 年: 被引用 188 件2017 年: 被引用 170 件2018 年: 被引用 194 件2019 年: 被引用 747 件2020 年: 被引用 890 件2021 年: 被引用 896 件2022 年: 被引用 835 件2023 年: 被引用 787 件2024 年: 被引用 1,140 件2025 年: 被引用 627 件2026 年: 被引用 8 件1972〜1999 年は被引用が無いため表示していません2001 年は被引用が無いため表示していません2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,789 件、この内訳の 25.3%中国: 引用元論文 1,704 件、この内訳の 15.5%イタリア: 引用元論文 623 件、この内訳の 5.7%イギリス: 引用元論文 568 件、この内訳の 5.2%日本: 引用元論文 514 件、この内訳の 4.7%ドイツ: 引用元論文 511 件、この内訳の 4.6%フランス: 引用元論文 456 件、この内訳の 4.1%スペイン: 引用元論文 427 件、この内訳の 3.9%カナダ: 引用元論文 329 件、この内訳の 3%韓国: 引用元論文 270 件、この内訳の 2.4%スイス: 引用元論文 251 件、この内訳の 2.3%オーストラリア: 引用元論文 238 件、この内訳の 2.2%
0%25.3%その他 21.1%

機関

分野

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology31.7%
  • Immunology and Microbiology3.7%
  • Engineering0.5%
  • Neuroscience0.3%
  • Computer Science0.3%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers9.1%
  • Lung Cancer Research Studies8.5%
  • Lung Cancer Treatments and Mutations8.4%
  • Cancer Genomics and Diagnostics6.2%
  • Neuroendocrine Tumor Research Advances3%
  • RNA modifications and cancer2.4%
  • その他62.4%

共著者

全論文

検索で開く
  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    著者: Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu - New England Journal of Medicine 2018 被引用: 3,507

  2. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

    著者: Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers - Cancer Cell 2021 被引用: 932

  3. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

    著者: Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Romain Banchereau, Bernadett Szabados, Kobe Yuen, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S. Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan - Nature 2021 被引用: 629

  4. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

    著者: Namrata S. Patil, Barzin Y. Nabet, Sören Müller, Hartmut Koeppen, Wei Zou, Jennifer M. Giltnane, Amelia Au‐Yeung, Shyam Srivats, Jason Cheng, Chikara Takahashi, Patrícia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William O’Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames - Cancer Cell 2022 被引用: 403

  5. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    著者: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 被引用: 1,195

  6. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    著者: Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang‐Jiun Wu, Jianhua Zhang, Jianhua Zhang, David S Barreto, Jacqulyne Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, K. G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian M. Alexander, Garrett M. Frampton, Lee A. Albacker, David S. Shames, Jianjun Zhang, Jianjun Zhang, John V. Heymach - Journal for ImmunoTherapy of Cancer 2021 被引用: 292

  7. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

    著者: Charles M. Rudin, Steffen Durinck, Eric Stawiski, John T. Poirier, Zora Modrušan, David S. Shames, Emily Anne Smith Bergbower, Yinghui Guan, James Shin, Joseph Guillory, Celina Sanchez Rivers, Catherine K. Foo, Deepali Bhatt, Jeremy Stinson, Florian Gnad, Peter M. Haverty, Robert Gentleman, Subhra Chaudhuri, Vasantharajan Janakiraman, Bijay S. Jaiswal, Chaitali Parikh, Wenlin Yuan, Zemin Zhang, Hartmut Koeppen, Thomas D. Wu, Howard M. Stern, Robert L. Yauch, Kenneth E. Huffman, Diego D’Ávila Paskulin, Peter B. Illei, Marileila Varella‐Garcia, Adi F. Gazdar, Frédéric J. de Sauvage, Richard Bourgon, John D. Minna, Malcolm V. Brock, Somasekar Seshagiri - Nature Genetics 2012 被引用: 1,098

  8. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

    著者: Barzin Y. Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M. Elhossiny, Minu K. Srivastava, Namrata S. Patil, Kiandra A. Smith, Rajiv Jesudason, Caleb Chan, Patrick Chang, Matthew Fernandez, Sandra Rost, Lisa McGinnis, Hartmut Koeppen, Carl M. Gay, John D. Minna, John V. Heymach, Joseph M. Chan, Charles M. Rudin, Lauren A. Byers, Stephen V. Liu, Martin Reck, David S. Shames - Cancer Cell 2024 被引用: 157

  9. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    著者: Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze - Nature Medicine 2023 被引用: 139

  10. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    著者: Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał T. Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, LCMC study investigators, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg - Nature Medicine 2022 被引用: 237

  11. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

    著者: Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y. Nabet, John Silva, Lisa McGinnis, Robert L. Hendricks, Katherine Nutsch, Karl L. Banta, Ellen Duong, Alexis Dunkle, Patrick Chang, Chia-Jung Han, Stephanie Mittman, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa L. Johnson, Delvys Rodríguez‐Abreu, Byoung Chul Cho, Antoîne Italiano, Ignacio Gil‐Bazo, Enriqueta Felip, Ira Mellman, Sanjeev Mariathasan, David S. Shames, Raymond D. Meng, Eugene Y. Chiang, Robert J. Johnston, Namrata S. Patil - Nature 2024 被引用: 123

  12. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    著者: Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski - Nature Medicine 2022 被引用: 170

  13. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    著者: Howard West, Mark L. McCleland, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David S. Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski - Journal for ImmunoTherapy of Cancer 2022 被引用: 151

  14. Molecular determinants of response to PD-L1 blockade across tumor types

    著者: Romain Banchereau, Ning Leng, Oliver A. Zill, Ethan S. Sokol, Gengbo Liu, Dean Pavlick, Sophia L. Maund, Lifen Liu, Edward E. Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe J. Assaf, Daniel Bower, Namrata S. Patil, Mark L. McCleland, David S. Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti S. Hegde, Thomas Powles - Nature Communications 2021 被引用: 171

  15. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

    著者: Solange Peters, Rafał Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Cheema, Manuel Cobo, Zoran Andrić, Carlos H. Barrios, Masafumi Yamaguchi, Éric Dansin, Pongwut Danchaivijitr, Melissa L. Johnson, Silvia Novello, Michael S. Mathisen, Sarah M. Shagan, Erica Schleifman, Jin Wang, Mark Yan, Simonetta Mocci, David Voong, David Fabrizio, David S. Shames, Todd Riehl, David R. Gandara, Tony Mok - Nature Medicine 2022 被引用: 111

  16. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

    著者: Manish A. Shah, Yung‐Jue Bang, Florian Lordick, María Alsina, Meng Chen, Stephen P. Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S. Shames, See Phan, David Cunningham - JAMA Oncology 2016 被引用: 301

  17. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

    著者: Pei-Hsuan Chen, Ling Cai, Kenneth E. Huffman, Chendong Yang, Jiyeon Kim, Brandon Faubert, Lindsey K. Boroughs, Bookyung Ko, Jessica Sudderth, Elizabeth A. McMillan, Luc Girard, Dong Chen, Michael Peyton, Misty Dawn Shields, Bo Yao, David S. Shames, Hyun Seok Kim, Brenda C. Timmons, Ikuo Sekine, Rebecca Britt, Stephanie Weber, Lauren A. Byers, John V. Heymach, Jing Chen, Michael A. White, John D. Minna, Guanghua Xiao, Ralph J. DeBerardinis - Molecular Cell 2019 被引用: 231

  18. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    著者: David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok - Journal of Clinical Oncology 2017 被引用: 326

  19. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

    著者: Triparna Sen, Pan Tong, C. Allison Stewart, Sandra Cristea, Aly Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson, John D. Minna, Julien Sage, Don L. Gibbons, Helen Piwnica‐Worms, John V. Heymach, Jing Wang, Lauren A. Byers - Cancer Research 2017 被引用: 195

  20. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

    著者: Bruna Pellini, Russell W. Madison, Merrida Childress, Shoshana T. Miller, Ole Gjoerup, Jason Cheng, Richard S.P. Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich, M. Ballinger, Minetta C. Liu, Amanda Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski - Clinical Cancer Research 2023 被引用: 45

  21. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

    著者: Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton - Cancer Discovery 2021 被引用: 101

  22. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    著者: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 被引用: 239

  23. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

    著者: Ling Cai, Hongyu Liu, Fang Huang, Junya Fujimoto, Luc Girard, Jun Chen, Li Y, Yu‐An Zhang, Dhruba Deb, Victor Stastny, Karine Pozo, Christin S. Kuo, Gaoxiang Jia, Chendong Yang, Wei Zou, Adeeb Alomar, Kenneth E. Huffman, Mahboubeh Papari-Zareei, Lin Yang, Benjamin J. Drapkin, Esra A. Akbay, David S. Shames, Ignacio I. Wistuba, Tao Wang, Jane E. Johnson, Guanghua Xiao, Ralph J. DeBerardinis, John D. Minna, Yang Xie, Adi F. Gazdar - Communications Biology 2021 被引用: 101

  24. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

    著者: Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu - Clinical Cancer Research 2015 被引用: 469